Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: pegaptanib sodium

First Posted Date: 2009-03-09

Last Posted Date: 2012-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 86

Registration Number: NCT00858208

Locations: 🇬🇷
Pfizer Investigational Site, Xanthi, Greece

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Phase 2

Completed

Conditions: Overactive Bladder
Neurogenic Detrusor Overactivity

Interventions: Drug: Fesoterodine

First Posted Date: 2009-03-09

Last Posted Date: 2011-11-24

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT00857896

Locations: 🇺🇸
Pfizer Investigational Site, Liberty Township, Ohio, United States

Non Interventional Study For Patients Treated With Somavert®

Completed

Conditions: Acromegaly

First Posted Date: 2009-03-09

Last Posted Date: 2009-09-02

Lead Sponsor: Pfizer

Target Recruit Count: 311

Registration Number: NCT00858143

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: 150 mg Suspension
Drug: 150 mg Tablet
Drug: 30 mg Suspension
Drug: 30 mg Tablet
Drug: 400 mg Suspension
Drug: 400 mg Tablet
Drug: 5 mg Suspension
Drug: 5 mg Tablet
Drug: 750 mg Suspension
Drug: 750 mg Tablet

First Posted Date: 2009-03-06

Last Posted Date: 2018-12-07

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00857571

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: PF-03893787
Drug: Placebo
Drug: Montelukast

First Posted Date: 2009-03-06

Last Posted Date: 2010-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00856687

Locations: 🇬🇧
Pfizer Investigational Site, Harrow, Middlesex, United Kingdom

Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: PF 03882845 and Placebo

First Posted Date: 2009-03-05

Last Posted Date: 2009-12-23

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT00856258

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: CP-690,550
Drug: Placebo

First Posted Date: 2009-03-05

Last Posted Date: 2013-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 795

Registration Number: NCT00856544

Locations: 🇻🇪
Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela

A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: voriconazole

First Posted Date: 2009-03-04

Last Posted Date: 2010-06-14

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00855101

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CP 690,550
Other: Placebo
Biological: Biologic TNFi
Drug: CP-690,550

First Posted Date: 2009-03-02

Last Posted Date: 2013-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 717

Registration Number: NCT00853385

Locations: 🇬🇧
Pfizer Investigational Site, Dudley, West Midlands, United Kingdom

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Hypertension, Pulmonary

Interventions: Drug: PF-00489791
Drug: placebo
Drug: sildenafil

First Posted Date: 2009-03-02

Last Posted Date: 2017-10-24

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT00853112

Locations: 🇺🇸
Pulmonary Associates, PA, Phoenix, Arizona, United States
🇺🇸
John C. Lincoln Hospital, North Mountain, Phoenix, Arizona, United States
🇺🇸
Shands at University of Florida, Gainesville, Florida, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy